Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX-HAIC plus tislelizumab as neoadjuvant therapy for resectable hepatocellular carcinoma beyond Milan criteria
ChiCTR2500098290Phase 2Recruiting
- Sponsor
- Tianjin Third Central Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC), sponsored by Tianjin Third Central Hospital. Primary endpoint: Major Pathological Response. Started Mar 2025; status: recruiting.
02
Drugs
tislelizumaboxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500098290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098290.